TY - JOUR
T1 - The effects of high dose interferon-β1a on plasma microparticles
T2 - Correlation with MRI parameters
AU - Lowery-Nordberg, Mary
AU - Eaton, Erin
AU - Gonzalez-Toledo, Eduardo
AU - Harris, Meghan K.
AU - Chalamidas, Kathrine
AU - McGee-Brown, Jeanie
AU - Ganta, Chaitanya V.
AU - Minagar, Alireza
AU - Cousineau, David
AU - Alexander, J. Steven
N1 - Funding Information:
This study was supported by an educational grant from EMD Serono, Inc., Boston, MA. JSA and CVG were partly funded by a Feist Cardiovascular Imaging Award.
PY - 2011/5/9
Y1 - 2011/5/9
N2 - Objectives: We previously reported a correlation between levels of microparticles carrying CD31 (PMP CD31+) and disease activity in MS. However, the effects of long term (12 month) treatment with high dose, high frequency interferon-β1a (Rebif™) on plasma levels of PMPCD31+, PMPCD146+, and PMPCD54+ and MRI measures of disease activity have not yet been assessed.Methods: During this prospective 1-year study, we used flow cytometry to measure changes in plasma microparticles (PMP) bearing CD31 (PMPCD31+), CD146 (PMPCD146+), and CD54/ICAM-1 (PMPCD54+) in 16 consecutive patients with relapsing-remitting MS (RRMS) before and after 3, 6, and 12 months of subcutaneous therapy with interferon-beta1a (44 micrograms, 3X weekly). At each visit, clinical exams and expanded disability status scale (EDSS) scores were recorded.Results: Plasma levels of PMPCD31+, and PMPCD54+ were significantly reduced by treatment with IFN-β1a. PMPCD146+ appeared to decrease only at 3 months and did not persist at 6 and 12 months (p = 0.0511). In addition, the decrease in plasma levels of PMPCD31+ and PMPCD54+ levels at 12 months were associated with a significant decrease in the number and volume of contrast enhancing T1-weigthed lesions.Conclusion: Our data suggest that serial measurement of plasma microparticles (PMP), particularly in the initial stages of MS (when neuro-inflammatory cascades are more intense), may serve as reliable and reproducible surrogate markers of response to IFN-β1a therapy for MS. In addition, the progressive decline in plasma levels of PMPCD31+ and PMPCD54+ further supports the concept that IFN-β1a exerts stabilizing effect on the cerebral endothelial cells during pathogenesis of MS.
AB - Objectives: We previously reported a correlation between levels of microparticles carrying CD31 (PMP CD31+) and disease activity in MS. However, the effects of long term (12 month) treatment with high dose, high frequency interferon-β1a (Rebif™) on plasma levels of PMPCD31+, PMPCD146+, and PMPCD54+ and MRI measures of disease activity have not yet been assessed.Methods: During this prospective 1-year study, we used flow cytometry to measure changes in plasma microparticles (PMP) bearing CD31 (PMPCD31+), CD146 (PMPCD146+), and CD54/ICAM-1 (PMPCD54+) in 16 consecutive patients with relapsing-remitting MS (RRMS) before and after 3, 6, and 12 months of subcutaneous therapy with interferon-beta1a (44 micrograms, 3X weekly). At each visit, clinical exams and expanded disability status scale (EDSS) scores were recorded.Results: Plasma levels of PMPCD31+, and PMPCD54+ were significantly reduced by treatment with IFN-β1a. PMPCD146+ appeared to decrease only at 3 months and did not persist at 6 and 12 months (p = 0.0511). In addition, the decrease in plasma levels of PMPCD31+ and PMPCD54+ levels at 12 months were associated with a significant decrease in the number and volume of contrast enhancing T1-weigthed lesions.Conclusion: Our data suggest that serial measurement of plasma microparticles (PMP), particularly in the initial stages of MS (when neuro-inflammatory cascades are more intense), may serve as reliable and reproducible surrogate markers of response to IFN-β1a therapy for MS. In addition, the progressive decline in plasma levels of PMPCD31+ and PMPCD54+ further supports the concept that IFN-β1a exerts stabilizing effect on the cerebral endothelial cells during pathogenesis of MS.
UR - http://www.scopus.com/inward/record.url?scp=79955676251&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955676251&partnerID=8YFLogxK
U2 - 10.1186/1742-2094-8-43
DO - 10.1186/1742-2094-8-43
M3 - Article
C2 - 21554694
AN - SCOPUS:79955676251
SN - 1742-2094
VL - 8
JO - Journal of Neuroinflammation
JF - Journal of Neuroinflammation
M1 - 43
ER -